Eam Investors, LLC Galectin Therapeutics Inc Transaction History

Eam Investors, LLC

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2018 Nov 08, 2018	SELL	$3.68 - $6.93 $803,818 - $1.51 Million	-218,429 Closed	0 $0
Q2 2018 Aug 03, 2018	SELL	$3.16 - $9.16 $318,395 - $922,943	-100,758 Reduced 31.57%	218,429 $1.39 Million
Q1 2018 May 14, 2018	BUY	$3.78 - $5.97 $1.21 Million - $1.91 Million	319,187 New	319,187 $1.51 Million

9.65M

1.16M

1.98M

Ticker GALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,426,000
Market Cap $73.7M
Description
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...

Get notified when there are updates to the investment portfolio of Eam Investors, LLC, based on Form 13F filings with the SEC.

Stay updated on Eam Investors, LLC with notifications on news.